Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Biocon Limited
  6. News
  7. Summary
    BIOCON   INE376G01013

BIOCON LIMITED

(BIOCON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biocon unit plans 15% stake sale to Serum Institute for access to vaccines

09/17/2021 | 06:00am EDT
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Pune

BENGALURU, Sept 17 (Reuters) - Biocon Ltd said late on Thursday its biologics unit will sell a 15% stake to a Serum Institute of India (SII) subsidiary for access to 100 million doses of vaccines annually for 15 years, including COVID-19 shots.

SII, which makes AstraZeneca's COVID-19 shot, branded as Covishield in India, is the world's largest vaccine maker.

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the initial years, the companies said.

The 15% stake in the Biocon unit is valued at more than $730 million, Biocon's Executive Chairperson Kiran Mazumdar-Shaw said.

The unit, which makes pharmaceutical ingredients, will gain a foothold in the vaccine manufacturing space following the deal.

As part of the deal, the Biocon unit and the SII subsidiary will make and distribute vaccines and antibody treatments.

Biocon Biologics will also invest in setting up a research division for vaccines, with SII Chief Executive Officer Adar Poonawalla getting a seat on the board of the Biocon unit.

SII also expects to ramp up its Covishield manufacturing capacity to 200 million doses per month, Poonawalla said at a media briefing on Friday.

While there is a current ban on COVID-19 vaccine exports in India, Poonawalla said SII was trying to strengthen its supply chain and source raw materials from within the country as well.

SII is also manufacturing and stockpiling Novavax Inc's COVID-19 vaccine, which is yet to be granted approval by the Indian health authorities.

In January, Abu Dhabi-based investment firm ADQ invested $75.47 million in Biocon Biologics for a 1.8% stake.

Biocon Ltd's shares rose as much as 4.6% early on Friday but gave up gains to trade 0.67% lower amid losses in the broader market.

($1 = 73.5350 Indian rupees) (Reporting by Shivani Singh and Rama Venkat in Bengaluru; Editing by Shounak Dasgupta)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.22% 8795 Delayed Quote.20.34%
BIOCON LIMITED -1.31% 347.65 Delayed Quote.-25.30%
NOVAVAX, INC. -4.59% 161.95 Delayed Quote.45.23%
All news about BIOCON LIMITED
10/05BIOCON : expands its Generic Formulations portfolio with the launch of Everolimus tablets ..
AQ
10/04BIOCON : Launches Cancer Treatment Drug Everolimus in US
MT
10/03Biocon Ltd Expands Its Generic Formulations Portfolio with the Launch of Everolimus Tab..
CI
09/26BIOCON : Insulin Manufacturing Unit in Malaysia Gets Six Observations from US FDA
MT
09/22India's Serum Institute to invest $68 mln in UK vaccine maker Oxford Biomedica
RE
09/17Biocon unit plans 15% stake sale to Serum Institute for access to vaccines
RE
09/16BIOCON : Biologics Forms Strategic Alliance with Serum Institute Life Sciences
MT
09/07BIOCON : Signs Settlement Agreement with US-Based Celgene in Cancer-Treatment Drug Patent ..
MT
07/29Biocon Biologics and Viatris Inc. Receive Approval for First Interchangeable Biosimilar..
CI
07/26BIOCON : Arm Gets License from US Company for COVID-19 Monoclonal Antibody
MT
More news
Financials
Sales 2022 83 477 M 1 113 M 1 113 M
Net income 2022 8 039 M 107 M 107 M
Net Debt 2022 28 796 M 384 M 384 M
P/E ratio 2022 51,2x
Yield 2022 0,30%
Capitalization 414 B 5 513 M 5 511 M
EV / Sales 2022 5,30x
EV / Sales 2023 4,22x
Nbr of Employees 13 500
Free-Float 34,7%
Chart BIOCON LIMITED
Duration : Period :
Biocon Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 347,65 INR
Average target price 391,17 INR
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Siddharth Mittal Chief Executive Officer, Director & MD
Indranil Sen Chief Financial Officer
Kiran Mazumdar-Shaw Executive Chairman
Manoj Kumar Pananchukunnath Head-Regulatory Sciences, Research & Development
Sandeep Nilkanth Athalye Head-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOCON LIMITED-25.30%5 502
GILEAD SCIENCES, INC.16.98%85 447
WUXI APPTEC CO., LTD.29.45%65 650
BIONTECH SE207.08%60 460
REGENERON PHARMACEUTICALS15.01%57 767
VERTEX PHARMACEUTICALS-23.03%47 190